D J Kwiatkowski
Overview
Explore the profile of D J Kwiatkowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
5308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rakaee M, Andersen S, Giannikou K, Paulsen E, Kilvaer T, Busund L, et al.
Ann Oncol
. 2023 Apr;
34(7):578-588.
PMID: 37100205
Background: We aim to implement an immune cell score model in routine clinical practice for resected non-small-cell lung cancer (NSCLC) patients (NCT03299478). Molecular and genomic features associated with immune phenotypes...
2.
Hernandez J, Wang X, Vazquez-Segoviano M, Lopez-Marfil M, Sobral-Reyes M, Moran-Horowich A, et al.
Nat Commun
. 2021 Nov;
12(1):6496.
PMID: 34764250
The lack of animal models for some human diseases precludes our understanding of disease mechanisms and our ability to test prospective therapies in vivo. Generation of kidney organoids from Tuberous...
3.
Treichel A, Kwiatkowski D, Moss J, Darling T
Br J Dermatol
. 2019 Jul;
182(1):235-237.
PMID: 31287558
No abstract available.
4.
Wang Y, Hong X, Wang J, Yin Y, Zhang Y, Zhou Y, et al.
Oncogene
. 2016 Jul;
36(6):756-765.
PMID: 27399332
Rheb is a Ras family GTPase, which binds to and activates mammalian target of rapamycin complex 1 (mTORC1) when GTP loaded. Recently, cancer genome sequencing efforts have identified recurrent Rheb...
5.
Wang F, Chen X, Li C, Sun Q, Chen Y, Wang Y, et al.
Oncogene
. 2013 Oct;
33(34):4352-8.
PMID: 24077282
Tuberous sclerosis complex 1 (TSC1) and TSC2 are suppressors of mechanistic target of rapamycin (mTOR). mTOR is the major component of two protein complexes: mTOR complex 1 (mTORC1) and mTORC2....
6.
Guo Y, Chirieac L, Bueno R, Pass H, Wu W, Malinowska I, et al.
Oncogene
. 2013 Jul;
33(24):3151-60.
PMID: 23851502
Mesothelioma is diagnosed in ∼2500 patients in the United States every year, most often arising in the pleural space, but also occurring as primary peritoneal mesothelioma. The vast majority of...
7.
Lin C, Zhang D, Kwiatkowski D, Shipley W, McDougal W, Yandell D
Urol Oncol
. 2011 Jan;
1(2):88-92.
PMID: 21224098
Allelic losses involving chromosome 9q occur in a significant percentage of bladder tumors. Experimental evidence suggests that a putative tumor suppressor gene located on this chromosome may play a role...
8.
Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, et al.
Oncogene
. 2010 Feb;
29(16):2346-56.
PMID: 20118985
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is limited by the development of resistance in...
9.
Liang M, Ma J, Chen L, Kozlowski P, Qin W, Li D, et al.
Oncogene
. 2009 Dec;
29(11):1588-97.
PMID: 19966866
Germline TSC1 or TSC2 mutations cause tuberous sclerosis complex (TSC), a hamartoma syndrome with lung involvement. To explore the potential interaction between TSC1 and KRAS activation in lung cancer, mice...
10.
Distinct clinical characteristics of tuberous sclerosis complex patients with no mutation identified
Camposano S, Greenberg E, Kwiatkowski D, Thiele E
Ann Hum Genet
. 2009 Jan;
73(2):141-6.
PMID: 19133941
Tuberous Sclerosis Complex (TSC) is a multi-system disorder that is highly variable in its clinical presentation. Current molecular diagnostic methods permit identification of mutations in either TSC1 or TSC2 in...